Julien Cassereau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Julien Cassereau has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Alaa Ghali
Department of General Surgery, Farhat Hached University Hospital, Sousse, Tunisia
2 shared publications - Christian Lavigne
Department of Internal Medicine and Clinical Immunology, Angers University Hospital, Angers, France
2 shared publications - Franck Letournel
Univ Angers, CHU Angers, Inserm, CNRS, MINT, SFR ICAT, Angers F-49000, France; Laboratoire de Neurobiologie et Neuropathologie, Centre Hospitalier Universitaire d'Angers, Angers, France
2 shared publications - Geoffrey Urbanski
Department of Orofacial Sciences, School of Dentistry, University of California, San Francisco, CA, USA
2 shared publications - P. Codron
Service de neurologie, CHU d'Angers, 4, rue Larrey, 49033 Angers, France
2 shared publications - Pascal Reynier
Department of Biochemistry and Molecular Biology, University Hospital of Angers, Angers, France
2 shared publications
Latest Publications
- 4 March 2025
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 152, 107876
Effects of virtual reality mindfulness on cognition and well-being in ALS: A randomized trial protocol
- 4 March 2025
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 152, 107876
Effects of virtual reality mindfulness on cognition and well-being in ALS: A randomized trial protocol
- 10 October 2023
- Published by Elsevier in Revue Neurologique
- Vol. 179 (10) , 1134-1144
Management of amyotrophic lateral sclerosis in clinical practice: Results of the expert consensus using the Delphi methodology
- 10 October 2023
- Published by Elsevier in Revue Neurologique
- Vol. 179 (10) , 1134-1144
Management of amyotrophic lateral sclerosis in clinical practice: Results of the expert consensus using the Delphi methodology
- 24 February 2023
- Published by Elsevier in Revue Neurologique
- Vol. 179 (6) , 548-562
Retinal vessels as a window on amyotrophic lateral sclerosis pathophysiology: A systematic review
- 24 February 2023
- Published by Elsevier in Revue Neurologique
- Vol. 179 (6) , 548-562
Retinal vessels as a window on amyotrophic lateral sclerosis pathophysiology: A systematic review
- 1 November 2021
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 32 (11) , 839-841
Towards personalized medicine for amyotrophic lateral sclerosis
- 1 November 2021
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 32 (11) , 839-841
Towards personalized medicine for amyotrophic lateral sclerosis
- 1 September 2020
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 79, 58-62
Differences in clinical features between small fiber and sensitive large fiber neuropathies in Sjögren's syndrome
- 1 September 2020
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 79, 58-62
Differences in clinical features between small fiber and sensitive large fiber neuropathies in Sjögren's syndrome
- Open Access
- 9 February 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (2) , 474
Strength of the Association of Elevated Vitamin B12 and Solid Cancers: An Adjusted Case-Control Study
The association between elevated plasma vitamin B12 (B12) level and solid cancers has been documented by two national registries. However, their design did not allow for the adjustment for other conditions associated with elevated B12. The objectives of this study were to confirm this association after the adjustment for all causes of elevated B12, and to study the variations according to the increasing B12 level, the type of cancers, and the presence of metastases. We compared 785 patients with B12 ≥ 1000 ng/L with 785 controls matched for sex and age with B12 < 1000 ng/L. Analyses were adjusted for the causes of elevated B12: myeloid blood malignancies, acute or chronic liver diseases, chronic kidney failure, autoimmune or inflammatory diseases, and excessive B12 supplementation. A B12 ≥ 1000 ng/L was associated with the presence of solid cancer without metastases (OR 1.96 [95%CI: 1.18 to 3.25]) and with metastases (OR 4.21 [95%CI: 2.67 to 6.64]) after adjustment for all elevated B12-related causes. The strength of the association rose with the increasing B12 level, in particular in cases of metastases. No association between liver cancers and elevated B12 level was found after adjustment for chronic liver diseases. In conclusion, unexplained elevated B12 levels should be examined as a possible marker of solid cancer.
- 9 February 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (2) , 474
Open AccessStrength of the Association of Elevated Vitamin B12 and Solid Cancers: An Adjusted Case-Control Study
The association between elevated plasma vitamin B12 (B12) level and solid cancers has been documented by two national registries. However, their design did not allow for the adjustment for other conditions associated with elevated B12. The objectives of this study were to confirm this association after the adjustment for all causes of elevated B12, and to study the variations according to the increasing B12 level, the type of cancers, and the presence of metastases. We compared 785 patients with B12 ≥ 1000 ng/L with 785 controls matched for sex and age with B12 < 1000 ng/L. Analyses were adjusted for the causes of elevated B12: myeloid blood malignancies, acute or chronic liver diseases, chronic kidney failure, autoimmune or inflammatory diseases, and excessive B12 supplementation. A B12 ≥ 1000 ng/L was associated with the presence of solid cancer without metastases (OR 1.96 [95%CI: 1.18 to 3.25]) and with metastases (OR 4.21 [95%CI: 2.67 to 6.64]) after adjustment for all elevated B12-related causes. The strength of the association rose with the increasing B12 level, in particular in cases of metastases. No association between liver cancers and elevated B12 level was found after adjustment for chronic liver diseases. In conclusion, unexplained elevated B12 levels should be examined as a possible marker of solid cancer.
- 1 January 2020
- Published by Elsevier in Experimental Neurology
- Vol. 323, 113069
Oxidative stress contributes differentially to the pathophysiology of Charcot-Marie-Tooth disease type 2K
- 1 January 2020
- Published by Elsevier in Experimental Neurology
- Vol. 323, 113069
Oxidative stress contributes differentially to the pathophysiology of Charcot-Marie-Tooth disease type 2K
- 1 April 2016
- Published by Elsevier in Pratique Neurologique - FMC
- Vol. 7 (2) , 93-99
Neuropathies héréditaires d’origine mitochondriale
- 1 April 2016
- Published by Elsevier in Pratique Neurologique - FMC
- Vol. 7 (2) , 93-99
Neuropathies héréditaires d’origine mitochondriale
- 1 May 2014
- Published by Elsevier in Revue Neurologique
- Vol. 170 (5) , 366-374
Inherited peripheral neuropathies due to mitochondrial disorders
- 1 May 2014
- Published by Elsevier in Revue Neurologique
- Vol. 170 (5) , 366-374
Inherited peripheral neuropathies due to mitochondrial disorders
- 1 January 2013
- Published by Elsevier in Neuroscience
- Vol. 228, 101-108
Axonal regeneration is compromised in NFH-LacZ transgenic mice but not in NFH-GFP mice
- 1 January 2013
- Published by Elsevier in Neuroscience
- Vol. 228, 101-108
Axonal regeneration is compromised in NFH-LacZ transgenic mice but not in NFH-GFP mice